Division of Gastroenterology, Hepatology


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Division of Gastroenterology, Hepatology

  1. 1. Division of Gastroenterology, Hepatology & Nutrition DIVISION PROFILE Number of Faculty 21 Number of Fellows Clinical Fellows 12 Research Fellows 9 Number of Graduate Students 1 Number of Other Students (full and part-time) 0 Number of Support Personnel 69 Annual Total Grant Support (direct) $3,953,356 Annual Total Industry Contracts (direct) $218,755 Number of Peer Reviewed Publications 51 Patient Encounters Outpatient 11,462 Inpatient 6,286FACULTY LISTINGMitchell B. Cohen, MD, CCHMC Endowed Chair, Professor of Pediatrics, Director, Division of Gastroenterology, Hepatology and Nutrition; Director, Digestive Health CenterWilliam F. Balistreri, MD, Dorothy M.M. Kersten, Professor of Pediatrics, Medical Director, Pediatric Liver Care Center; Associate Chair for Subspecialty Training, Department of Pediatrics; Editor, Journal of PediatricsMichael D. Bates, MD, PhD, Assistant Professor of PediatricsJorge A. Bezerra, MD, Professor of Pediatrics, Director of Research, Division of Gastroenterology, Hepatology and Nutrition; Director, Biliary Atresia Center; Associate Director, Digestive Health CenterJohn C. Bucuvalas, MD, Professor of Pediatrics, Associate Medical Director, Pediatric Liver Care Center; Director of Clinical Operations, Division of Gastroenterology, Hepatology and NutritionKathleen M. Campbell, MD, Assistant Professor of PediatricsLee A. Denson, MD, Associate Professor of Pediatrics, Director, Training Program in Pediatric Gastroenterology, Hepatology and NutritionMichael K. Farrell, MD, Professor of Pediatrics, Chief of StaffXiaonan Han, PhD, Research InstructorJames E. Heubi, MD, Professor of Pediatrics, Director, General Clinical Research Center; Assistant Dean for Clinical Research, University of Cincinnati College of MedicineAjay Kaul, MD, Associate Professor of Pediatrics, Director, GI Motility Disorders CenterSamuel A Kocoshis, MD, Professor of Pediatrics, Director, Nutrition and Intestinal Care CenterMike A. Leonis, MD, PhD, Instructor of Pediatrics, Associate Fellowship Director, Training Program in Pediatric Gastroenterology, Hepatology and NutritionM. Susan Moyer, MD, Professor of Pediatrics, Director, Schubert-Martin Inflammatory Bowel Disease CenterPhilip E. Putnam, MD, Associate Professor of Pediatrics, Director, Endoscopy Services; Medical Director, Cincinnati Center for Eosinophilic DisordersJeffrey A. Rudolph, MD, Assistant Professor of PediatricsNoah Shroyer, PhD, Assistant Professor of Pediatrics, Associate Fellowship Director, Training Program in Pediatric Gastroenterology, Hepatology and NutritionKris Steinbrecher, PhD, Assistant Professor of PediatricsGitit Tomer, MD, Assistant Professor of PediatricsStavra Xanthakos, MD, Assistant Professor of Pediatrics, Medical Director, Comprehensive Weight Management CenterNada Yazigi, MD, Assistant Professor of PediatricsPage 104 Cincinnati Children’s Research Foundation 2006–07 Annual Report
  2. 2. OVERVIEWThe overall goals of the Division are 1) to be theleader in the care of children withgastrointestinal and liver disease by providingsafe, effective, efficient, equitable and familycentered care, and 2) to improve patient care bythe development of new diagnostic andtherapeutic strategies for children with digestivediseases through basic and translational research.The Division is organized to advance ourstrategic goals and to match scientific prioritieswith specific clinical disorders, i.e., disease-based First Row: N. Yazigi, W. Balistreri, K. Steinbrecher, K. Campbell, X. Han ; Back Row:research, so that we can have the greatest impact J. Bezerra, M. Cohen, N. Shroyer, M. Leonis, L. Denson, S. Kocoshis, ; R. Kohli, M.on “Changing the Outcome” for pediatric Bates, M.S. Moyerdigestive diseases. Although progress is notalways linear, basic research identifies unique opportunities for translational research and to more definitive patient-basedstudies such as clinical trials. Once new treatments are in place, outcomes and health care delivery research allowmaximization of the benefits of the translated basic science work to children with digestive diseases. Among these diseases, wehave identified key pediatric diseases as research themes to improve digestive health for children through better treatmentsand outcomes: biliary atresia, inflammatory bowel disease (IBD), and obesity – three of the initial targets of the DiseaseSpecific Outcomes and Innovations Project (DSIOP) to integrate research into patient care – as well as eosinophilicgastrointestinal disorders (EGIDs), liver and intestinal failure and liver and intestinal transplantation, and developmental andmotility disorders of the gastrointestinal tract. Active clinical research programs are ongoing for all of these target diseases.The Division supports and participates in a number of multidisciplinary centers of clinical excellence including the SchubertMartin IBD Center, the Cincinnati Center for Eosinophilic Disorders and the Colorectal Center. We also are home to orparticipate in a number of NIH funded translational research centers including the Biliary Atresia Research Consortium,Cholestatic Liver Disease Consortium, Studies in Pediatric Liver Disease (SPLIT), the Acute Liver Failure Network (ALF),Adolescent Bariatrics: Assessing Benefits and Risks, the Enteric Vaccine and Treatment Evaluation Unit (VTEU) and theCincinnati Digestive Health Center. We have a strong commitment to professional education including an outstanding NIHfunded Fellowship Training Program. The Division also has active health services research programs to enable us to be theleader in improvement of outcomes and family centered care, which include participation in the PIBDnet IBD collaborative.HIGHLIGHTSClinical CareOur clinical care efforts are centered on important chronic diseases that will allow us to improve digestive health throughbetter treatments and outcomes. These target diseases include biliary atresia (BA), inflammatory bowel disease (IBD),eosinophilic esophagitis (EE), liver and intestinal failure and transplantation, motility disorders, anorectal malformations andobesity. In each case we are strengthening the integration of disease based research into our clinical care models and enrollingpatients in clinical protocols. These efforts are facilitated by interdisciplinary clinical and research centers and their programleaders including the: Schubert-Martin IBD Center (M. Susan Moyer), Cincinnati Center for Eosinophilic Disorders (P.Putnam), Aerodigestive and Sleep Center (P. Putnam, A. Kaul), Interdisciplinary Feeding Team (A. Kaul), Pediatric LiverCare Center (W. Balistreri, J. Bucuvalas), and Nutrition and Intestinal Care Center (NICC) (S. Kocoshis).The Division has ongoing major quality improvement efforts relating to: a) IBD, and participates in the PedIBD Network -North American collaborative improvement project. We have implemented CCHMC Evidence Based Guidelines in IBD foruse of mercaptopurine and infliximab. b) NICC, and has developed a clinical registry to improve care for the approximately100 patients with intestinal failure. c) Access, and has significantly decreased the waiting time for new patient visits to <10days with referral letters sent back to primary care providers in an average of <3 days.We have partnered with the nurses on B5E and B5W and the newly appointed Sr. Clinical Director for the GI BusinessUnit, Lisa Keegan, RN to further advance family centered rounds and a culture of safety. This is exemplified in ourmultidisciplinary weekly team meetings and the daily discussion of progress towards discharge goals with the family andmedical team and the read back of newly prescribed medications on rounds to enhance patient safety.2006–07 Annual Report Cincinnati Children’s Research Foundation Page 105
  3. 3. ResearchThe Research endeavors of the Division are highly aligned with the clinical care programs. Prominent is cutting edge researchfocused on BA and related disorders (J. Bezerra, J. Heubi). This includes investigation of molecular mechanisms ofBA/cholestasis, development of new diagnostic tools, e.g., the Jaundice chip, studies on nutritional and steroid treatment afterBA surgery, and inborn errors of bile acid metabolism. Research programs related to liver transplantation (J. Bucuvalas, K.Campbell, M. Leonis, N. Yazigi) include investigation of patient and allograft survival, and gene polymorphisms that increaserisk for renal dysfunction after transplantation. Programs related to IBD and EE (M. Cohen, T. Denson, X. Han, P. Putnam,N. Shroyer, K. Steinbrecher, G. Tomer) include studies on inflammatory mechanisms of IBD, growth hormone treatment todecrease mucosal inflammation, genotype-phenotype correlations in IBD, molecular control of eosinophils, biomarkers ofEE, a randomized placebo controlled trial for treatment of EE and separate longitudinal outcomes studies of patients with EEand IBD. Research programs related to intestinal failure and anorectal malformations (M. Bates, M. Cohen, J. Heubi, S.Kocoshis, J. Rudolph, N. Shroyer) include genetics of anorectal malformations, molecular control of intestinal proliferationand development, control of intestinal apoptosis in animal models and transplant recipients, outcomes of intestinaltransplantation, and diagnostic tests for fat malabsorption. We have partnered with the medical and surgical bariatricprograms to investigate risk factors for obesity complications (S. Xanthakos) and Dr. R. Kohli has joined the faculty in July toinvestigate basic mechanisms leading to non-alcoholic steatohepatitis.In addition, the Division became the home this year to the NIH supported Cincinnati Digestive Health Center, the onlyNIDDK Core Center dedicated to pediatric digestive disease research (M. Cohen, J. Bezerra).EducationThe NIH supported Fellowship Training Program continues to produce outstanding graduates who predominantly enteracademic medicine (>80% over the past 10 years). This year our graduates took positions at the University of Pittsburgh (V.Venkat), Maine Medical Center (R. Carey), San Diego Naval Medical Center (L. Boamah) and Cincinnati Children’sHospital Medical Center (M. Garin-Laflam). The fellowship program has 4 fellows per year with opportunities for advancedresearch fellowship and a one year program in pediatric transplant hepatology. Dr. Heubi led a national effort whichculminated this year in the first match for pediatric gastroenterology fellowship.TRAININGLynelle Boamah, MD PL-6 Naval Medical Center - Portsmouth, VirginiaRebecca Carey, MD PL-6 University of UtahMonica Garin-Laflam, MD PL-6 Jackson Memorial HospitalVeena Venkat, MD PL-6 Cincinnati Childrens Hospital Medical CenterJill Dorsey, MD PL-5 Medical University of South CarolinaAlexander Miethke, MD PL-5 Cincinnati Childrens Hospital Medical CenterBrad Pasternak, MD PL-5 S.U.N.Y. Downstate Medical CenterScott Pentiuk, MD PL-5 Cincinnati Childrens Hospital Medical CenterKatie Moyer, MD PL-4 Oregon Health and Sciences UniversityMelanie Rhue, MD PL-4 Carolinas Medical CenterCharles Samson, MD PL-4 University of North Carolina at Chapel HillBella Zeisler, MD PL-4 New York UniversityIngrid Jurickova, MD Second Medical Faculty, Charles University, Prague, Czech RepublicAvedis Kazanjian, PhD University of LouisvilleCong Liu, PhD University of CincinnatiElizabeth Mann, PhD University of CincinnatiUrsula Matte, PhD Universidade Federal do Rio Grande do Sul, BrazilSujit Mohanty, PhD All Indian Medical Institute, New Delhi, IndiaKumar Shanmukhappa, PhD Kansas University, MissouriPranav Shivakumar, PhD New Delhi University, IndiaCynthia Wetzel, PhD University of CincinnatiPage 106 Cincinnati Children’s Research Foundation 2006–07 Annual Report
  4. 4. GRANTS, CONTRACTS AND INDUSTRY AGREEMENTSGrant and Contract Awards Annual Direct/Project Period DirectBalistreri, W Pegylated Interferon +/- Ribavirin for Children with HCV National Institutes of Health (Johns Hopkins University subcontract) U01 DK 067767 09/30/03 – 08/31/06 $18,810/$45,600Bates, M Genetics of Anorectal Malformations in Humans AGA Foundation for Digestive Health & Nutrition 07/01/06 – 06/30/07 $25,000Bezerra, J Clinical Center for Biliary Atresia: Etiopathogenesis and Clinical Outcome National Institutes of Health U01 DK 062497 09/15/02 – 05/31/07 $159,329/$644,075 Immunologic Dysfunction in Biliary Atresia National Institutes of Health R01 DK 064008 08/15/03 – 06/30/07 $189,198/$820,003 Molecular Determinants of Phenotypes in Biliary Atresia National Institutes of Health R56 DK 070820 07/01/06 – 06/30/11 $186,000/$372,000 The Plasminogen System and Liver Repair National Institutes of Health R01 DK 055710 02/15/07 – 11/30/10 $205,000/$820,000 Pre-clinical Trial to Block Progression of Duct Obstruction in Biliary Atresia American Liver Foundation 07/01/06 – 06/30/08 $90,909/$181,818Boamah, L An Education Program for Adolescents with Inflammatory Bowel Disease Procter and Gamble Pharmaceuticals R01 DK 068463 05/01/05 – 01/31/10 $361,149/$1,653,077Bucuvalas, J Studies of Pediatric Liver Transplantation National Institutes of Health (The EMMES Corporation subcontract) U01 DK 061693 05/14/04 – 03/31/09 $18,121/$52,000 Functional Outcomes in Pediatric Liver Transplantation National Institutes of Health (Children’s Memorial Hospital subcontract) R01 HD 045694 04/01/05 – 03/31/10 $14,912/$91,255 Functional Outcomes in Pediatric Liver Transplantation National Institutes of Health (Children’s Memorial Hospital subcontract – per patient) R01 HD 045694 04/01/05 – 03/31/10 $13,087/$243,290 A Multi-Center Group to Study Acute Liver Failure in Children – Project #1 National Institutes of Health (Children’s Hospital of Pittsburgh) U01 DK 072146 09/01/05 – 08/31/07 $133,238Campbell, K Pharmacogenetics of Post-Transplant Renal Dysfunction American Liver Foundation 07/01/05 – 06/30/07 $75,000/$150,000Cohen, M Expression and Function of the Guanylin Ligand Family National Institutes of Health R01 DK 047318 02/01/05 – 11/30/09 $208,600/$1,100,000 Pediatric Gastroenterology and Nutrition Training Grant National Institutes of Health T32 DK 007727 07/01/05 – 06/30/10 $347,064/$1,771,477 Planning Grant for CholeraGarde Study Avant Immunotherapeutics, Inc 07/13/06 – 07/12/07 $10,0002006–07 Annual Report Cincinnati Children’s Research Foundation Page 107
  5. 5. Evaluation of Control Measures Against Diseases Other than AIDS: Part C-Cholera National Institutes of Health N01 AI 025459 06/01/02 – 05/31/07 $0/$2,202,030 Digestive Health Center: Bench to Bedside Research in Pediatric Digestive Disease National Institutes of Health P30 DK 078392 06/01/07– 05/31/12 $727,500/$3,637,500Denson, L Cytokine Regulation of Liver Growth Hormone Signaling National Institutes of Health R01 DK 068164 04/01/06 – 12/31/10 $160,000/$1,000,000Han, X Characterization of STAT5b as a Novel Therapeutic Target in Crohn’s Disease Crohn’s & Colitis Foundation of America 01/01/06 – 12/31/08 $76,524/$229,737Heubi, J Intraluminal Effects of Cholesterol Absorption/Synthesis National Institutes of Health R01 DK 068463 05/01/05 – 01/31/10 $361,149/$1,653,077Leonis, M The RON Receptor Tyrosine Kinase in Hepatic Tumorigene National Institutes of Health K08 CA 111819 07/01/06 – 06/30/11 $123,000/$615,000Miethke, A Genetic Basis of Cholestatic Liver Disease Children’s Hospital Association R01 DK 068463 07/01/06 – 07/31/07 $50,000Pasternak, B Pediatric Physician Scientist Program Award National Institutes of Health (Yale University subcontract) K12 HD 000850 07/01/06 - 06/30/07 $94,750Rudolph, J Cyclic-AMP Induced Crypt Cell Survival in the Intestine National Institutes of Health K08 DK 066297 02/01/04 – 12/31/08 $115,751/$578,750Shroyer, N Intestinal Secretory Lineage Differentiation and Function AGA/FDHN Research Scholars Award 07/01/06 – 06/30/08 $16,250/$32,500 Intestinal Secretory Lineage Differentiation and Function National Institutes of Health K01 DK071686 09/01/06 - 07/31/09 $123,015/$371,138Steinbrecher, K A Protective Role for GSK-3b During Initiation of Inflammatory Bowel Disease Childrens Digestive Health and Nutrition Foundation 11/15/06 – 11/14/08 $50,000/$100,000 Current Year Direct $3,953,356Page 108 Cincinnati Children’s Research Foundation 2006–07 Annual Report
  6. 6. Industry ContractsBalistreri, W Digestive Care $4,555 Gilead Sciences $4,910Heubi, J Mead Johnson $53,394 PPD Development $85,013Denson, L Genentech $68,987 Centacor $1,896 Current Year Direct Receipts $218,755 TOTAL $4,172,111PUBLICATIONSBalistreri WF. Advances in hepatology: inherited disorders of bile acid transport or synthesis. Gastroenterol Hepatol. 2007May;3(5):343-5.Balistreri WF, Bezerra JA, Ryckman FC. Biliary atresia and other disorders of the extrahepatic bile ducts. In: Suchy FJ, SokolRJ, Balistreri WF, eds. Liver disease in children. 3rd ed. Cambridge ; New York: Cambridge University Press 2007:247-69.Erickson N, Balistreri WF. Sclerosing cholangitis. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver disease in children. 3rded. Cambridge ; New York: Cambridge University Press 2007:459-77.Hochman JA, Balistreri WF. Acute and chronic viral hepatitis. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver disease inchildren. 3rd ed. Cambridge ; New York: Cambridge University Press 2007:369-446.Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associatedliver disease: a meeting review. Hepatology. 2007 May;45(5):1313-23.Bates MD, Dunagan DT, Welch LC, Kaul A, Harvey RP. The Hlx homeobox transcription factor is required early in entericnervous system development. BMC Dev Biol. 2006;6:33.Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesus ML, Alghothani M, BensonDM, Jr., Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. Hlx homeobox transcription factor negatively regulatesinterferon-gamma production in monokine-activated natural killer cells. Blood. 2007 Mar 15;109(6):2481-7.Falcone RA, Jr., Levitt MA, Pena A, Bates M. Increased heritability of certain types of anorectal malformations. J PediatrSurg. 2007 Jan;42(1):124-7; discussion 7-8.Allen SR, Jafri M, Donnelly B, McNeal M, Witte D, Bezerra J, Ward R, Tiao GM. Effect of rotavirus strain on the murinemodel of biliary atresia. J Virol. 2007 Feb;81(4):1671-9.Bezerra JA. The next challenge in pediatric cholestasis: deciphering the pathogenesis of biliary atresia. J Pediatr GastroenterolNutr. 2006 Jul;43 Suppl 1:S23-9.de Carvalho E, Ivantes CA, Bezerra JA. Extrahepatic biliary atresia: current concepts and future directions. J Pediatr (Rio J).2007 Mar-Apr;83(2):105-20.Liu C, Aronow BJ, Jegga AG, Wang N, Miethke A, Mourya R, Bezerra JA. Novel resequencing chip customized to diagnosemutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology. 2007 Jan;132(1):119-26.Lugea A, Nan L, French SW, Bezerra JA, Gukovskaya AS, Pandol SJ. Pancreas recovery following cerulein-inducedpancreatitis is impaired in plasminogen-deficient mice. Gastroenterology. 2006 Sep;131(3):885-99.Shanmukhappa K, Sabla GE, Degen JL, Bezerra JA. Urokinase-type plasminogen activator supports liver repair independentof its cellular receptor. BMC Gastroenterol. 2006;6:40.Bucuvalas JC, Campbell KM, Cole CR, Guthery SL. Outcomes after liver transplantation: keep the end in mind. J PediatrGastroenterol Nutr. 2006 Jul;43 Suppl 1:S41-8.Campbell KM, Arya G, Ryckman FC, Alonso M, Tiao G, Balistreri WF, Bezerra JA. High prevalence of alpha-1-antitrypsinheterozygosity in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2007 Jan;44(1):99-103.2006–07 Annual Report Cincinnati Children’s Research Foundation Page 109
  7. 7. Burrow TA, Cohen MB, Bokulic R, Deutsch G, Choudhary A, Falcone RA, Jr., Grabowski GA. Gaucher disease: progressivemesenteric and mediastinal lymphadenopathy despite enzyme therapy. J Pediatr. 2007 Feb;150(2):202-6.Konikoff MR, Blanchard C, Kirby C, Buckmeier BK, Cohen MB, Heubi JE, Putnam PE, Rothenberg ME. Potential of bloodeosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin GastroenterolHepatol. 2006 Nov;4(11):1328-36.Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assaad AH,Aceves SS, Putnam PE, Rothenberg ME. A randomized, double-blind, placebo-controlled trial of fluticasone propionate forpediatric eosinophilic esophagitis. Gastroenterology. 2006 Nov;131(5):1381-91.Walker WA, Sherman P, Cohen M, Barnard J. State of pediatric gastroenterology, hepatology, and nutrition: 2006 andbeyond. Gastroenterology. 2007 Jan;132(1):434-6.Wu S, Shin J, Zhang G, Cohen M, Franco A, Sears CL. The Bacteroides fragilis toxin binds to a specific intestinal epithelialcell receptor. Infect Immun. 2006 Sep;74(9):5382-90.Chen W, Cai SY, Xu S, Denson LA, Soroka CJ, Boyer JL. Nuclear receptors RXRalpha:RARalpha are repressors for humanMRP3 expression. Am J Physiol Gastrointest Liver Physiol. 2007 May;292(5):G1221-7.Denson LA. Adding fuel to the fire: STAT3 priming of gastric tumorigenesis. Gastroenterology. 2006 Oct;131(4):1342-4.Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, PuchalskiJT, Hauck DM, Trapnell BC. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. NEngl J Med. 2007 Feb 8;356(6):567-79.Han X, Benight N, Osuntokun B, Loesch K, Frank SJ, Denson LA. Tumour necrosis factor alpha blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis. Gut. 2007 Jan;56(1):73-81.Han X, Osuntokun B, Benight N, Loesch K, Frank SJ, Denson LA. Signal transducer and activator of transcription 5bpromotes mucosal tolerance in pediatric Crohns disease and murine colitis. Am J Pathol. 2006 Dec;169(6):1999-2013.Scharte M, Han X, Uchiyama T, Tawadrous Z, Delude RL, Fink MP. LPS increases hepatic HIF-1alpha protein andexpression of the HIF-1-dependent gene aldolase A in rats. J Surg Res. 2006 Oct;135(2):262-7.Heubi JE, Finkel Y, Molleston J, Alonsom E, Olivia-Hemker M. The match for US pediatric gastroenterology and nutritionfellowships. J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):411-2.Setchell KD, Heubi JE. Defects in bile acid biosynthesis--diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2006 Jul;43Suppl 1:S17-22.Wang Y, Jones PJ, Woollett LA, Buckley DD, Yao L, Granholm NA, Tolley EA, Heubi JE. Effects of chenodeoxycholic acidand deoxycholic acid on cholesterol absorption and metabolism in humans. Transl Res. 2006 Jul;148(1):37-45.Yao L, Horn PS, Heubi JE, Woollett LA. The liver plays a key role in whole body sterol accretion of the neonatal GoldenSyrian hamster. Biochim Biophys Acta. 2007 Apr;1771(4):550-7.Boesch RP, Daines C, Willging JP, Kaul A, Cohen AP, Wood RE, Amin RS. Advances in the diagnosis and management ofchronic pulmonary aspiration in children. Eur Respir J. 2006 Oct;28(4):847-61.Brady MS, Garson JL, Krug SK, Kaul A, Rickard KA, Caffrey HH, Fineberg N, Balistreri WF, Stevens JC. An enteric-coatedhigh-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am DietAssoc. 2006 Aug;106(8):1181-6.Pentiuk SP, Miller CK, Kaul A. Eosinophilic esophagitis in infants and toddlers. Dysphagia. 2007 Jan;22(1):44-8.Wessel JJ, Kocoshis SA. Nutritional management of infants with short bowel syndrome. Semin Perinatol. 2007Apr;31(2):104-11.Wetzel CC, Leonis MA, Dent A, Olson MA, Longmeier AM, Ney PA, Boivin GP, Kader SA, Caldwell CC, Degen SJ, WaltzSE. Short-form Ron receptor is required for normal IFN-gamma production in concanavalin A-induced acute liver injury.Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G253-61.Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE.Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-cateninactivation. Cancer Res. 2006 Dec 15;66(24):11967-74.Page 110 Cincinnati Children’s Research Foundation 2006–07 Annual Report
  8. 8. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, Otley A, Evans J, Pfefferkorn M, Rosh J, Rothbaum R,Kugathasan S, Mezoff A, Wyllie R, Tolia V, delRosario JF, Moyer MS, Oliva-Hemker M, Leleiko N. The natural history ofcorticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006 Sep;4(9):1118-23.Mack DR, Langton C, Markowitz J, LeLeiko N, Griffiths A, Bousvaros A, Evans J, Kugathasan S, Otley A, Pfefferkorn M,Rosh J, Mezoff A, Moyer S, Oliva-Hemker M, Rothbaum R, Wyllie R, delRosario JF, Keljo D, Lerer T, Hyams J.Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007 Jun;119(6):1113-9.Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, Pfefferkorn M, Mezoff A, Rosh J, Tolia V, Otley A,Griffiths A, Moyer MS, Oliva-Hemker M, Wyllie R, Rothbaum R, Bousvaros A, Del Rosario JF, Hale S, Lerer T.Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohns disease.Clin Gastroenterol Hepatol. 2006 Sep;4(9):1124-9.Assaad AH, Putnam PE, Collins MH, Akers RM, Jameson SC, Kirby CL, Buckmeier BK, Bullock JZ, Collier AR, KonikoffMR, Noel RJ, Guajardo JR, Rothenberg ME. Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J AllergyClin Immunol. 2007 Mar;119(3):731-8.Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assaad AH, RothenbergME. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006 Dec;118(6):1312-9.Zur KB, Putnam PE, Rutter MJ. Combined retrograde and anterograde hypopharyngeal puncture and dilatation in a childwith complete hypopharyngeal stenosis. Int J Pediatr Otorhinolaryngol. 2007 Jan;71(1):153-7.Elitsur N, Lorenz JN, Hawkins JA, Rudolph JA, Witte D, Yang LE, McDonough AA, Cohen MB. The proximal convolutedtubule is a target for the uroguanylin-regulated natriuretic response. J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S74-81.Nathan JD, Rudolph JA, Kocoshis SA, Alonso MH, Ryckman FC, Tiao GM. Isolated liver and multivisceral transplantationfor total parenteral nutrition-related end-stage liver disease. J Pediatr Surg. 2007 Jan;42(1):143-7.Rudolph JA, Pratt J, Mourya R, Steinbrecher KA, Cohen MB. Novel mechanism of cyclic AMP mediated extracellular signalregulated kinase activation in an intestinal cell line. Cell Signal. 2007 Jun;19(6):1221-8.Shroyer NF, Helmrath MA, Wang VY, Antalffy B, Henning SJ, Zoghbi HY. Intestine-specific ablation of mouse atonalhomolog 1 (Math1) reveals a role in cellular homeostasis. Gastroenterology. 2007 Jun;132(7):2478-88.Inge TH, Xanthakos SA, Zeller MH. Bariatric surgery for pediatric extreme obesity: now or later? Int J Obes (Lond). 2007Jan;31(1):1-14.Xanthakos SA, Daniels SR, Inge TH. Bariatric surgery in adolescents: an update. Adolesc Med Clin. 2006 Oct;17(3):589-612; abstract x.Xanthakos SA, Inge TH. Nutritional consequences of bariatric surgery. Curr Opin Clin Nutr Metab Care. 2006Jul;9(4):489-96.Xanthakos SA, Inge TH. Extreme pediatric obesity: weighing the health dangers. J Pediatr. 2007 Jan;150(1):3-5.2006–07 Annual Report Cincinnati Children’s Research Foundation Page 111